Repare Therapeutics Highlights Early RP-3500 Data In Solid Tumor Patients

Vandana Singh
1 min read
0
In this article:

Repare Therapeutics Inc (NASDAQ: RPTX) has announced the presentation of monotherapy dose selection and safety data from its Phase 1/2 TRESR trial of RP-3500.

  • RP-3500 is a potent and selective oral small molecule inhibitor of ATR (Ataxia-Telangiectasia and Rad3-related protein kinase) for solid tumors with specific synthetic-lethal genomic alterations.

  • The analysis confirmed the recommended phase 2 dose (160mg 3 days/4 days off).

  • Anemia was the most common reported toxicity, with less than 25% of patients experiencing grade 3 toxicities.

  • Related: Repare Therapeutics Reveals Early Efficacy Data From Lead Program In Solid Tumor Setting.

  • A dose modification plan that includes two alternative dosing schedules were established to mitigate the on-target toxicity of anemia and maintain patients on an RP-3500 dosing schedule that targets anti-tumor activity.

  • The Company will present updated clinical data from 120 patients enrolled in the Phase 1/2 TRESR trial in 1H of 2022.

  • Price Action: RPTX shares are down 1.07% at $14.27 during the market session on the last check Monday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement

Recommended Stories